12:00 AM
Nov 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

S/GSK1349572: Phase III started

Shionogi and ViiV Healthcare LLC, a JV between GlaxoSmithKline and Pfizer, began the double-blind, international Phase III SPRING-2 trial to compare once-daily 50 mg S/GSK1349572 vs. twice-daily 400 mg Isentress raltegravir in about 788 treatment-naïve HIV-1-infected patients....

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >